Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 3/2007

01-06-2007 | Commentary

Recently published papers: Therapies failed, disputed, and beneficent

Author: Gareth Williams

Published in: Critical Care | Issue 3/2007

Login to get access

Abstract

A recent meta-analysis puts another nail in the coffin of a therapy that held great promise for management of acute respiratory distress syndrome. Two papers further highlight the growing controversy surrounding the safety profile of drotrecogin alfa (activated) and increase the clamour for a new independent trial. Also covered are steroids and their role in preventing postoperative atrial fibrillation, and success in instituting hypothermia after cardiac arrest. Finally, which form of renal replacement therapy should we be using in the intensive care unit?
Literature
1.
Adhikari NKJ, Burns KEA, Friedrich JO, Granton JT, Cook DJ, Meade MO: Effect of nitric oxide on oxygenation in acute lung injury: systematic review and meta-analysis. BMJ 2007, 334: 779-782. 10.1136/bmj.39139.716794.55PubMedCentralCrossRefPubMed
2.
Sokol J, Jacobs SE, Bohn D: Inhaled nitric oxide for acute hypoxic respiratory failure in children and adults: a meta-analysis. Anesth Analg 2003, 97: 989-998. 10.1213/01.ANE.0000078819.48523.26CrossRefPubMed
3.
Bertolini G, Rossi C, Anghileri A, Livigni S, Addis A, Poole D: Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a national survey. Intensive Care Med 2007, 33: 426-434. 10.1007/s00134-007-0554-xCrossRefPubMed
4.
Kanji S, Perreault MM, Chant C, Williamson D, Burry L: Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study. Intensive Care Med 2007, 33: 517-523. 10.1007/s00134-007-0555-9CrossRefPubMed
5.
Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344: 699-709. 10.1056/NEJM200103083441001CrossRefPubMed
6.
Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T, et al.: Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE. Crit Care Med 2005, 33: 2266-2277. 10.1097/01.CCM.0000181729.46010.83CrossRefPubMed
7.
Eichacker PQ, Natanson C: Increasing evidence that the risks of rhAPC may outweigh its benefits. Intensive Care Med 2007, 33: 396-399. 10.1007/s00134-007-0556-8CrossRefPubMed
8.
Halonen J, Halonen P, Jarvinen O, Taskinen P, Auvinen T, Tarkka M, Hippelainen M, Juvonen T, Hartikainen J, Hakala T: Corticosteroids for the prevention of atrial fibrillation after cardiac surgery. JAMA 2007, 297: 1562-1567. 10.1001/jama.297.14.1562CrossRefPubMed
9.
The Hypothermia after Cardiac Arrest Study Group: Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002, 346: 549-556. 10.1056/NEJMoa012689CrossRef
10.
Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, Smith K: Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002, 346: 557-563. 10.1056/NEJMoa003289CrossRefPubMed
11.
Arrich J, The European Resuscitation Council Hypothermia After Cardiac Arrest Registry Study Group: Clinical application of mild therapeutic hypothermia after cardiac arrest. Crit Care Med 2007, 35: 1041-1047. 10.1097/01.CCM.0000259383.48324.35CrossRefPubMed
12.
Bell M, Granath F, Schon S, Ekbom A, Martling CR: Continuous renal replacement therapy is associated with less chronic renal failure than intermittent haemodialysis after acute renal failure. Intensive Care Med 2007, 33: 773-780. 10.1007/s00134-007-0590-6CrossRefPubMed
Metadata
Title
Recently published papers: Therapies failed, disputed, and beneficent
Author
Gareth Williams
Publication date
01-06-2007
Publisher
BioMed Central
Published in
Critical Care / Issue 3/2007
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc5931

Other articles of this Issue 3/2007

Critical Care 3/2007 Go to the issue

Letter

Video of dantrolene effectiveness on neuroleptic malignant syndrome associated muscular rigidity and tremor

Research

Cooling and hemodynamic management in heatstroke: practical recommendations

Commentary

The simple and the simpler in pneumonia diagnosis

Research

Nucleated red blood cells in the blood of medical intensive care patients indicate increased mortality risk: a prospective cohort study

Commentary

Metabolic effects of phosphodiesterase III inhibitors: another reason to promote their use?

Commentary

Is tissue Doppler echocardiography the Holy Grail for the intensivist?